Panacea Biotec Limited is an India-based pharmaceutical and biotechnology company with research, manufacturing and marketing capabilities. The Company is engaged in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food and nutrition products in India and international markets. Its segments include vaccines and formulations. It has specialized in the development of fully liquid combination vaccines that can be stored at 2-8 degree Celsius temperature. Its vaccine portfolio includes EasySix (DTwP-Hib-HepB-IPV), EasyFive-TITM (DTwP-Hib-HepB), EasyFour-TI (DTwP-Hib), EasyFourPol (DTwP-IPV) and Bivalent oral polio vaccine (type-1 and type-3). Its pipeline vaccines include NucoVac 11, DengiALL and Td (tetanus and diphtheria - reduced). Its pharmaceutical formulation products include Sitcom Tablets and Sitcom Cream. Its nutrition product brand names include ChilRunfull, ChilRun 7+ and ChilRun NoSucrose.As of 25 May 2026, Panacea Biotec share price is ₹419.05. The stock opened at ₹422.95, compared to its previous close of ₹418.55. During today's trading session, Panacea Biotec share price moved in the range of ₹416.85 to ₹433.45, with an average price of ₹425.15 for the day. Looking at its last 52-week, the stock has touched a low of ₹416.85 and a high of ₹433.45. On the performance front, Panacea Biotec share price has increased by 21.27% over the last six months and is down 16.94% on a year-on-year basis.
The market capitalization of Panacea Biotec is ₹2,565 Crs, with a P/E ratio of -314.9 and a dividend yield of 0.00%.